<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089855</url>
  </required_header>
  <id_info>
    <org_study_id>CTEG111ZMA01</org_study_id>
    <nct_id>NCT01089855</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain</brief_title>
  <official_title>Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of TegretolÂ® in Diabetes Neuropathy Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The trial is designed to evaluate the efficacy and tolerability of carbamazepine in&#xD;
      neuropathic pain in diabetic patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease of neuropathic pain in diabetic patients using Brief Pain Inventory scale (BPI)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the tolerability of carbamazepine (including Adverse Events, Serious Adverse Events and abnormal laboratory finding)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Carbamazepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <arm_group_label>Carbamazepine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes patients with Diabetes neuropathy DN4 &gt; or equal to 4&#xD;
&#xD;
          -  Male or female aged from 21 to 65 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  HbA1C &lt; 11%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior Hospitalization for Acido- cetosis&#xD;
&#xD;
          -  Prior hospitalization for severe hypoglycemia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  Diabetes foot&#xD;
&#xD;
          -  AVB (auriculo-ventricular conduction disturbance)&#xD;
&#xD;
          -  Patient treated by antidepressant drugs&#xD;
&#xD;
          -  Patient treated with other antiepileptic drug&#xD;
&#xD;
          -  Patients with blood ion disturbance&#xD;
&#xD;
          -  Patient with neutropenia&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Bladder Adenoma&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Creatinin clearance &lt; 60 ml/ minute&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Morocco</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Brief Pain Inventory</keyword>
  <keyword>DN4 questionnaire</keyword>
  <keyword>ElectroCardioGram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

